Glenmark Life Sciences Limited
NSE:GLS.NS
1096.1 (INR) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | |||||||||||||||||
| Net Income
| 1,114.83 | 979.37 | 1,187.65 | 1,187.37 | 1,354.5 | 1,463.57 | 1,049.93 | 1,068.78 | 1,087.33 | 988.97 | 1,037.13 | 1,152.01 | 1,009.13 | 1,046.84 | 933.61 | 724.7 | 810.66 |
| Depreciation & Amortization
| 0 | 0 | 131.77 | 131.29 | 126.12 | 115.17 | 107.63 | 99.35 | 0 | 0 | 0 | 0 | 0 | 78.81 | 78.01 | 0 | 0 |
| Deferred Income Tax
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation
| 0 | 43.75 | 0 | 0 | 0 | 31.85 | 0 | 0 | 0 | 34.98 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change In Working Capital
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 835.17 | -260.5 | 0 | 0 |
| Accounts Receivables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,013.39 | -358.42 | 0 | 0 |
| Change In Inventory
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -52.95 | 56.38 | 0 | 0 |
| Change In Accounts Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -125.27 | 41.54 | 0 | 0 |
| Other Non Cash Items
| -1,114.83 | -979.37 | -1,187.65 | -1,187.37 | -1,354.5 | -1,495.42 | -1,049.93 | -1,068.78 | -1,087.33 | -1,023.95 | -1,037.13 | -1,152.01 | -1,009.13 | -183.37 | -110.92 | -724.7 | -810.66 |
| Operating Cash Flow
| 0 | 0 | 263.54 | 262.58 | 252.24 | 31.85 | 215.26 | 198.7 | 0 | 34.98 | 0 | 0 | 0 | 1,777.45 | 640.2 | 0 | 0 |
| Investing Activities: | |||||||||||||||||
| Investments In Property Plant And Equipment
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -243.82 | -136.4 | 0 | 0 |
| Acquisitions Net
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases Of Investments
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sales Maturities Of Investments
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activites
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20.73 | 9.5 | 0 | 0 |
| Investing Cash Flow
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -264.55 | -126.9 | 0 | 0 |
| Financing Activities: | |||||||||||||||||
| Debt Repayment
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -467.82 | -568.78 | 0 | 0 |
| Financing Cash Flow
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -467.82 | -568.78 | 0 | 0 |
| Other Information: | |||||||||||||||||
| Effect Of Forex Changes On Cash
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 166.36 | 0 | 0 |
| Net Change In Cash
| 0 | 0 | 263.54 | 262.58 | 252.24 | 31.85 | 215.26 | 198.7 | 0 | 34.98 | 0 | 0 | 0 | 1,045.08 | 110.88 | 0 | 0 |
| Cash At End Of Period
| 0 | 0 | 4,694.26 | 4,430.72 | 3,346.21 | 3,093.97 | 3,860.87 | 3,645.61 | 0 | 34.98 | 0 | 0 | 1,155.96 | 1,155.96 | 110.88 | 0 | 0 |